Jerry, I figure the BAM supply is now down to approx 3.5 mil shares, if one assumes that 60% of the 13.5 mil shares in sell side volume since last Wednesday came from BAM. We could use a few more big volume days to clear it out, otherwise it'll take longer.
I figure there probably won't be much news until the SA mini-results come out ~early Oct ('mini' because it's only an interim analysis, and also because it'll probably be data on only 6 or 7 patients). This should generate enough volume to clear out any remaining BAM remnants from the July financing.
The BAM supply can then be replenished by up to 6.9 mil warrant shares after Oct 17, but the pps would have to be over the exercise price of .34 cents, so that's a 48% pps gain from the current pps, and it would take another few cents above .34 to make it worth their while to start exercising. Of course Cortex would get some cash from the exercising, up to approx $2.4 mil.
Then the next event should be the partner/licensing 'deal' or MA announcement around late October/early Nov. That's the key event I'm invested for. I'm figuring we get to .50 cents or better under most partnering/MA scenarios, and perhaps up to .75 - 1.00 is possible if there's a buyout (trying to be realistic with these figures).
Market Data 
Markets 
